Please login to the form below
TNBC
This page shows the latest TNBC news and features for those working in and with pharma, biotech and healthcare.
Merck’s Keytruda combined with chemotherapy could benefit thousands of breast cancer patients
It is estimated that around 15% of all breast cancers – with more than 8, 000 cases per years in the UK – are diagnosed as TNBC. ... The trial, funded by MSD, involved 1, 174 patients across 21 countries with previously untreated stage 2 or 3 TNBC.
Latest news
-
Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
Effective treatment options are extremely limited in TNBC compared with other breast cancer types and the chance of recurrence and metastases is higher. ... While patients whose tumours express PD-L1 can receive immunotherapies like Merck/MSD’s
-
Merck receives first breast cancer approval in Europe for Keytruda
Triple-negative breast cancer (TNBC) is an aggressive form of the disease with a high recurrence rate and more commonly diagnosed in in people who are younger than 40, who are ... Keytruda is approved in the same indication in the US as well as for
-
Gilead’s Trodelvy set for EU approval in breast cancer
This is good news for European patients with TNBC, the most aggressive form of the disease, which is more frequently diagnosed in younger and premenopausal women as well as being more ... Effective treatment options are extremely limited for patients
-
Tecentriq withdrawn in hard-to-treat breast cancer in US
TNBC patients generally experience rapid progression and shorter overall survival compared to other subtypes of breast cancer. ... In July, the FDA gave full approval to Keytruda in both advanced/metastatic and in early-stage TNBC.
-
Merck’s Keytruda gains two more approvals in Japan
This approval is particularly important for the country as so-called ‘triple-negative’ breast cancer (TNBC) is more prevalent in Japan than in the US, with around 15% of patients with ... breast cancer in Japan diagnosed with TNBC.
More from news
Approximately 5 fully matching, plus 36 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Trop2 is a transmembrane glycoprotein overexpressed in many epithelial cancer cells, including TNBC.
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior therapies
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... trocar. Further, TAVO has already proven to show robust efficacy in difficult-to-treat patient populations, including metastatic melanoma
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- My body. My choice. Are we all talking about the same thing?
- BeiGene announces positive phase 3 trial results for liver cancer treatment
- Sanofi halts recruitment for trials assessing MS treatment
- Merck and Cerevance to research novel targets in Alzheimer’s disease
- Michael J Fox Foundation awards Koneksa second research grant
- FDA approves Bot Image’s AI software for the detection and diagnosis of prostate cancer
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Eli Lilly to make bebtelovimab commercially available to US states from August
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Achieving communication excellence by targeting the right channel at the right time
- Oral biologics delivery still elusive
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- Strategic commitment
- ...
- KOL Ambassador Program & Podcast Creation: A Customer Story
- ...
- Animation: Living With
- The journey from the patient's perspective...
